Healthcare Sys & Biz27 Jul 2026
Proline Hydroxylation: A New Target for RNA Metabolism and Cell Cycle Regulation?Read article
The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Jideytro offers new hope for ROS1-positive NSCLC after prior therapy
The FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, providing a new option for this rare subtype.
How non-animal models are redefining oncology drug safety
The FDA issued draft guidance to reduce animal testing for oncology drugs, allowing sponsors to use non-animal methods for certain safety and efficacy assessments.
Lung Transplants Extend Survival for Select Stage 4 Cancer Patients
Lung transplantation significantly extended survival for a highly selected cohort of stage 4 lung cancer patients whose disease had not spread beyond the chest.
Forget sterile tumors: Cancers house unique microbiomes
Sitting for Long Stretches Linked to Higher Cancer Mortality Risk
South African Scientists Decipher Cancer's Survival Strategy
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.
Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview
A recent review outlines the mechanisms, diagnosis, and management of metabolic dysfunction associated steatotic liver disease (MASLD) in adults.
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Nearly 1 in 10 With Primary Biliary Cholangitis Have CKD
Heart Failure Treatment in 2026: A Clinical Overview
Heart failure management has changed substantially over the past decade. This clinical overview covers the four pillars of guideline-directed medical therapy, the role of device therapy, and emerging treatments entering practice in 2026.
How lipid packing dictates caveolae stability at the plasma membrane
Lipid packing density plays a critical role in confining caveolae to the plasma membrane, influencing their stability and function in cellular processes.
Smartphones and Pacemakers: Separating Fact from Electromagnetic Fiction
Modern smartphones pose minimal risk of electromagnetic interference with pacemakers and ICDs, provided a safe distance is maintained.
Cardiovascular risk: Why men die earlier, women live sicker
AI in the ED: Can algorithms truly accelerate acute cardiac care?
Pulsed Field Ablation: A New Frontier for Atrial Fibrillation?
Tzield expands its reach: A new option for recently diagnosed pediatric type 1 diabetes
The FDA approved Tzield (teplizumab) for pediatric patients with recently diagnosed Stage 3 type 1 diabetes, marking an expansion of its indication.
What Is an SGLT2 Inhibitor? Mechanism, Indications, and Evidence
SGLT2 inhibitors block renal glucose reabsorption to lower blood sugar and protect the heart and kidneys. A clinical primer on mechanism, approved agents, key trial evidence, and safety.
Targeted Therapy Reverses Weight Gain From Rare Cause of Obesity
A targeted therapy effectively reversed weight gain in patients with a rare genetic form of obesity, demonstrating significant reductions in body weight.
Why lifestyle advice alone still dominates obesity searches
Online GLP-1 Prescriptions Often Lack Clinical Oversight
Metabolic Syndrome: Is it accelerating your patients' brain aging?
Eptinezumab Improves Cognitive Symptoms in Migraine Patients
Eptinezumab significantly reduced cognitive symptoms in patients with migraine, offering a new dimension of relief beyond headache frequency.
Roche Halts Huntington's Gene-Silencing Programs
Roche has ended its gene-silencing programs for Huntington's disease, including tominersen, after clinical trials failed to show benefit or raised safety concerns.
Football Headers Linked to Cognitive Decline, Neurodegeneration
Repeated head impacts from football headers correlate with increased risk of cognitive impairment and neurodegenerative disease, particularly in former professional players.
Multiple MyelomaDonor T-cells prevent CMV complications in blood cancer patients
Get the full story6 min readMAHA Monday: The Rush to Publish and Its Clinical Fallout
Get the full story11 min readLiso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment
Get the full story11 min readNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
Get the full story7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
Get the full story8 min readMonoclonal Antibodies May Complicate Transfusion Testing
Get the full story7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
Get the full story7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Get the full story8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Get the full story7 min readMacrophages: Dual Role in Haematological Malignancies Explored
Get the full story7 min read
Arthritis Psoriatic
Drug Resistance MicrobialARHGAP36: A new survival predictor for neuroblastoma patients
Severe VT in ischaemic cardiomyopathy: Why current care isn't enough
Obesity as Disease: Who Benefits from the Redefinition?
Cognitive Rehabilitation Eases Long-COVID Brain Fog
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30MunichAug 28 – 31 2026
GLP-1 Agonists: Do They Prevent Heart Disease in the General Population?
GLP-1 receptor agonists reduce cardiovascular risk in obese individuals with established CVD, but their benefit in primary prevention remains unclear.
Factor XIa Inhibitors After Heart Attack: A New Antithrombotic Path?
Factor XIa inhibitors offer a novel antithrombotic strategy after myocardial infarction, aiming for reduced bleeding risk compared to current agents.
Eplontersen: Can a new RNAi therapy change ATTR-CM outcomes?
Eplontersen significantly reduced transthyretin protein levels and improved clinical endpoints in ATTR amyloid cardiomyopathy.
Aficamten: A New Path for Non-Obstructive Hypertrophic Cardiomyopathy?
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition with limited treatment options. The drug targets cardiac myosin, reducing contractility and improving symptoms.
Ruling Out Heart Attacks Faster: The PRESC1SE-MI Study's ED Impact
The PRESC1SE-MI study demonstrated a novel algorithm using high-sensitivity troponin I can safely rule out myocardial infarction in the emergency department within one hour.
Do Statins Still Benefit Patients Over 70 Without Prior CVD?
The STAREE trial investigated statin use for primary prevention in individuals over 70, challenging long-held assumptions about cardiovascular benefit in this age group.
Can Factor XIa Inhibitors Reduce Post-MI Bleeding Without Compromising Efficacy?
Factor XIa inhibitors aim to reduce thrombotic events in acute coronary syndrome patients while minimizing bleeding risk, a critical balance in post-MI care.
Faster Heart Attack Rule-Out: Can PRESC1SE-MI Deliver on ED Efficiency?
A new strategy for ruling out myocardial infarction in emergency departments, using high-sensitivity troponin and clinical risk scores, demonstrated high safety and reduced length of stay.
Aficamten targets non-obstructive HCM, a disease with no approved drug
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition lacking specific approved therapies.
Do Statins Prevent Dementia in Healthy Older Adults? STAREE Trial Weighs In
The STAREE trial investigated statin use in healthy adults over 70, finding no reduction in dementia incidence but a modest cardiovascular benefit.
Why Transthyretin Amyloid Cardiomyopathy Remains Underdiagnosed
Transthyretin amyloid cardiomyopathy (ATTR-CM) often presents with non-specific symptoms, leading to significant diagnostic delays and missed opportunities for early intervention.
ESC Congress 2026: The 59 Pivotal Trials You Need to Know
Fifty-nine pivotal trials will present at ESC Congress 2026, covering major cardiovascular disease areas from heart failure to arrhythmia.
Lipoprotein(a) Risk: Define, Test Early, Optimise Management
Elevated lipoprotein(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease. Early identification and management are critical.
GLP-1 Agonists: Do They Prevent Heart Disease in the General Population?
GLP-1 receptor agonists reduce cardiovascular risk in obese individuals with established CVD, but their benefit in primary prevention remains unclear.
Factor XIa Inhibitors After Heart Attack: A New Antithrombotic Path?
Factor XIa inhibitors offer a novel antithrombotic strategy after myocardial infarction, aiming for reduced bleeding risk compared to current agents.
Eplontersen: Can a new RNAi therapy change ATTR-CM outcomes?
Eplontersen significantly reduced transthyretin protein levels and improved clinical endpoints in ATTR amyloid cardiomyopathy.
Aficamten: A New Path for Non-Obstructive Hypertrophic Cardiomyopathy?
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition with limited treatment options. The drug targets cardiac myosin, reducing contractility and improving symptoms.
Ruling Out Heart Attacks Faster: The PRESC1SE-MI Study's ED Impact
The PRESC1SE-MI study demonstrated a novel algorithm using high-sensitivity troponin I can safely rule out myocardial infarction in the emergency department within one hour.
Do Statins Still Benefit Patients Over 70 Without Prior CVD?
The STAREE trial investigated statin use for primary prevention in individuals over 70, challenging long-held assumptions about cardiovascular benefit in this age group.
Can Factor XIa Inhibitors Reduce Post-MI Bleeding Without Compromising Efficacy?
Factor XIa inhibitors aim to reduce thrombotic events in acute coronary syndrome patients while minimizing bleeding risk, a critical balance in post-MI care.
Faster Heart Attack Rule-Out: Can PRESC1SE-MI Deliver on ED Efficiency?
A new strategy for ruling out myocardial infarction in emergency departments, using high-sensitivity troponin and clinical risk scores, demonstrated high safety and reduced length of stay.
Aficamten targets non-obstructive HCM, a disease with no approved drug
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition lacking specific approved therapies.
Do Statins Prevent Dementia in Healthy Older Adults? STAREE Trial Weighs In
The STAREE trial investigated statin use in healthy adults over 70, finding no reduction in dementia incidence but a modest cardiovascular benefit.
Why Transthyretin Amyloid Cardiomyopathy Remains Underdiagnosed
Transthyretin amyloid cardiomyopathy (ATTR-CM) often presents with non-specific symptoms, leading to significant diagnostic delays and missed opportunities for early intervention.
ESC Congress 2026: The 59 Pivotal Trials You Need to Know
Fifty-nine pivotal trials will present at ESC Congress 2026, covering major cardiovascular disease areas from heart failure to arrhythmia.
Lipoprotein(a) Risk: Define, Test Early, Optimise Management
Elevated lipoprotein(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease. Early identification and management are critical.
